TW200624125A - Compositions and methods for increasing HDL and HDL-2b levels - Google Patents
Compositions and methods for increasing HDL and HDL-2b levelsInfo
- Publication number
- TW200624125A TW200624125A TW094100736A TW94100736A TW200624125A TW 200624125 A TW200624125 A TW 200624125A TW 094100736 A TW094100736 A TW 094100736A TW 94100736 A TW94100736 A TW 94100736A TW 200624125 A TW200624125 A TW 200624125A
- Authority
- TW
- Taiwan
- Prior art keywords
- hdl
- compositions
- methods
- levels
- increasing
- Prior art date
Links
- 230000001965 increasing effect Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- WSYRBHQWMXTCHQ-SFIKJRKMSA-N (2s)-n-[(2r)-1-[[(2s)-1-[[(2r)-1-[[(2r)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-[[( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 WSYRBHQWMXTCHQ-SFIKJRKMSA-N 0.000 abstract 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51589103P | 2003-10-29 | 2003-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200624125A true TW200624125A (en) | 2006-07-16 |
Family
ID=34549456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094100736A TW200624125A (en) | 2003-10-29 | 2005-01-11 | Compositions and methods for increasing HDL and HDL-2b levels |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050148556A1 (enExample) |
| EP (1) | EP1684704A2 (enExample) |
| JP (1) | JP2007509965A (enExample) |
| CA (1) | CA2543170A1 (enExample) |
| TW (1) | TW200624125A (enExample) |
| WO (1) | WO2005041878A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| US20080058292A1 (en) * | 2003-10-29 | 2008-03-06 | Raif Tawakol | Method for increasing HDL and HDL-2b levels |
| US20090069275A1 (en) * | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
| WO2008091338A1 (en) * | 2007-01-23 | 2008-07-31 | Reddy Us Therapeutics, Inc. | Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia |
| WO2008100249A1 (en) * | 2007-02-13 | 2008-08-21 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| US20170042821A1 (en) * | 2007-07-01 | 2017-02-16 | Vitalis Llc | Combination tablet with chewable outer layer |
| US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| WO2009033072A1 (en) * | 2007-09-05 | 2009-03-12 | Raif Tawakol | Compositions and methods for controlling cholesterol levels |
| RU2010151944A (ru) * | 2008-05-20 | 2012-06-27 | Серенис Терапьютикс С.А. (Fr) | Ниацин и нспвс для комбинированной терапии |
| US20110123575A1 (en) * | 2008-06-02 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Modified release niacin formulations |
| RU2010153904A (ru) * | 2008-06-02 | 2012-07-20 | Др. Редди'С Лабораторис Лтд. (In) | Ниацин-содержащие композиции с модифицированным высвобождением |
| WO2013063078A1 (en) | 2011-10-28 | 2013-05-02 | Vitalis Llc | Anti-flush compositions |
| US20160030463A1 (en) * | 2013-03-13 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating or preventing insulin resistance or abnormal levels of circulating lipids in a mammal |
| US10695309B2 (en) * | 2017-03-31 | 2020-06-30 | Western New England University | Sustained-release liothyronine formulations, method of preparation and method of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3312593A (en) * | 1965-03-10 | 1967-04-04 | Carter Prod Inc | Anti-inflammatory compositions of aspirin and niacin |
| US4080472A (en) * | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| AU5787996A (en) * | 1995-04-19 | 1996-11-07 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
| EP1017390B1 (en) * | 1997-07-31 | 2007-04-18 | Kos Life Sciences, Inc. | Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form |
| US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
| US7323496B2 (en) * | 1999-11-08 | 2008-01-29 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
| US6680340B2 (en) * | 2000-08-21 | 2004-01-20 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
| JP2004513090A (ja) * | 2000-09-27 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体 |
| EP1343763A1 (en) * | 2000-11-20 | 2003-09-17 | Bristol-Myers Squibb Company | Pyrodone derivatives as ap2 inhibitors |
-
2004
- 2004-10-29 EP EP04817473A patent/EP1684704A2/en not_active Withdrawn
- 2004-10-29 CA CA002543170A patent/CA2543170A1/en not_active Abandoned
- 2004-10-29 WO PCT/US2004/035910 patent/WO2005041878A2/en not_active Ceased
- 2004-10-29 US US10/977,508 patent/US20050148556A1/en not_active Abandoned
- 2004-10-29 JP JP2006538281A patent/JP2007509965A/ja active Pending
-
2005
- 2005-01-11 TW TW094100736A patent/TW200624125A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050148556A1 (en) | 2005-07-07 |
| JP2007509965A (ja) | 2007-04-19 |
| WO2005041878A2 (en) | 2005-05-12 |
| EP1684704A2 (en) | 2006-08-02 |
| CA2543170A1 (en) | 2005-05-12 |
| WO2005041878A3 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005034998A3 (en) | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions | |
| IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
| WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| IL162838A0 (en) | Compositions and methods for prevention and treatment peptide-of amyloid- related disorders | |
| UA91560C2 (ru) | Соединения ряда изоиндолимидов, их композиция и применение | |
| IL184047A0 (en) | Methods and compositions for treating amyloid-related diseases | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MY160041A (en) | Compositions and methods for treating parasitic infections | |
| IL175306A0 (en) | Compositions and dosage forms for enhanced absorption | |
| TW200716139A (en) | Methods and compositions for managing psychotic disorders | |
| WO2005041878A3 (en) | Compositions and methods for increasing hdl and hdl-2b levels | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| UA91678C2 (en) | Synergism of galactooligosaccharides and polyfructose | |
| IL217713A0 (en) | Compounds and compositions for delivering active agents | |
| TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
| MX2009013779A (es) | Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r. | |
| ZA200702375B (en) | Quinazolines useful as modulators of ion channels | |
| ATE531721T1 (de) | Cyanoaminochinolone als gsk-3-inhibitoren | |
| IL169793A0 (en) | Synergistic compositions and methods for potentiating anti-oxidative activity | |
| MX2009003912A (es) | Metodos y composiciones usando compuestos inmunomoduladores para el tratamiento y manejo de enfermedades bacterianas por espiroquetas y otras bacterias intracelulares obligadas. | |
| ZA200705881B (en) | Formulations and treatments for well-being | |
| MXPA05010388A (es) | Dispositivos, metodos y composiciones para prevenir la restenosis. | |
| ATE399558T1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
| MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. |